Polypeptide variants with increased heparin-binding ability
CA 2362496 C · Owner: Osteopharma Inc. · Inventors: Sebald, Walter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention pertains to polypeptide variants with increased heparin-binding ability. , Increased heparin-binding ability is achieved by addition insertion, and/or , substitution of , an amino acid sequence X1X2X3X4X5X6 (SEQ ID NO. 1 or NO.2). Polypeptide variants , according to the invention are particularly suited for stimulation of chondrogenesis, osteogenesis, and wound healing. The invention also pertains to amino acid molecules , that encode said polypeptide variants host cells containing said nucleic acid molecules, and processes for producing the polypeptide variants.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 27, 2000 and granted April 19, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 27, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 27, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.